Hemab Therapeutics Inc. Common Stock
COAG | NASDAQ
$41.16
-$0.29 (-0.70%)
Nov 2, 2026, 10:40 AM ET · Market open
TTM Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 |
|---|---|---|
Cash & Equivalents | 237.37M | 49.86M |
Short-Term Investments | 220.09M | 113.67M |
Long-Term Investments | n/a | n/a |
Other Long-Term Assets | 2.29M | 4.24M |
Receivables | n/a | 1.43M |
Inventory | n/a | n/a |
Other Current Assets | n/a | n/a |
Total Current Assets | 464M | 169.43M |
Property-Plant & Equipment | 1.5M | 1.59M |
Goodwill & Intangibles | n/a | n/a |
Total Long-Term Assets | 3.78M | 5.83M |
Total Assets | 467.78M | 175.26M |
Account Payables | 6.23M | 5.68M |
Deferred Revenue | n/a | n/a |
Short-Term Debt | n/a | n/a |
Other Current Liabilities | n/a | 1.29M |
Total Current Liabilities | 12.94M | 13.19M |
Long-Term Debt | n/a | n/a |
Other Long-Term Liabilities | n/a | 360.17M |
Total Long-Term Liabilities | 566K | 360.69M |
Total Liabilities | 13.51M | 373.88M |
Total Debt | 1.03M | 1.06M |
Book Value | 454.27M | -198.62M |
Book Value Per Share | 15.09 | -4.49 |
Common Stock | 454.27M | n/a |
Retained Earnings | n/a | -204.55M |
Comprehensive Income | n/a | -439K |
Shareholders Equity | 454.27M | -198.62M |
Total Investments | 220.09M | 113.67M |
Add to Watchlist
Select watchlists to add or remove COAG